Suzhou Ribo Life Science Co., Ltd. (Ribo) is a company dedicated to discovering, developing and commercializing innovative oligonucleotide therapeutics (mainly siRNA, also ASO and aptamer), and is the pioneer and leading player in this sector in China.
Ribo has built a vertically integrated R&D platform including various aspects of proprietary technologies, facilities and a highly qualified professional team that have enabled the development of a significant pipeline of oligonucleotide therapeutics.
We cherish all opportunities of research and development cooperations in the broad field of oligonucleotide therapeutics, including license-out & license-in of pipeline products and technologies, collaboration on targeting of novel targets and development of novel technologies
2024
Ribo signed up with Boehringer Ingelheim to develop new treatments for people with liver diseases.
2023
Ribo granted Qilu Pharmaceutical Co., Ltd. the rights to develop, manufacture and commercialize RBD7022 in Greater China region.
2017
Ribo acquired the exclusive rights to develop, manufacture and commercialize 3 antisense oligonucleotide therapeutics licensed from Ionis Pharmaceuticals Inc. in China.
2016
Ribo acquired the exclusive rights to develop, manufacture and commercialize BT-200 licensed from Band Therapeutics Inc. in Greater China.
2013
Ribo obtained the rights licensed from Life Technologies, Inc. (acquired by Thermo Fisher Scientific in 2014) to apply the liposome delivery technology for development of oligonucleotide therapeutics in China.
2012
Ribo entered into a strategic partnership with Quark Pharmaceuticals Inc. to fuel the development and commercialization of RNAi drugs in most of Asian countries.
